NCT00517491View on ClinicalTrials.gov

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Acromegaly
Interventions
DRUG

lanreotide (Autogel formulation)

120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.

Trial Locations (1)

06720

Centro Médico Nacional Siglo XXI, IMSS, Mexico City

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT00517491 - Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) | Biotech Hunter | Biotech Hunter